<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872179</url>
  </required_header>
  <id_info>
    <org_study_id>16-21157-B</org_study_id>
    <nct_id>NCT04872179</nct_id>
  </id_info>
  <brief_title>International Registry of Patients With Alpha Thalassemia</brief_title>
  <acronym>ATM Registry</acronym>
  <official_title>International Prospective Registry of Patients With Alpha Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international prospective registry of patients with Alpha thalassemia to&#xD;
      understand the natural history of the disease and the outcomes of fetal therapies, with the&#xD;
      overall goal of improving the prenatal management of patients with Alpha thalassemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this registry is to prospectively and retrospectively collect data on patients who&#xD;
      are diagnosed with alpha thalassemia major and other alpha thalassemia mutations. Data&#xD;
      collected will be used to:&#xD;
&#xD;
        1. Identify patient outcomes of therapies.&#xD;
&#xD;
        2. Improve clinical management of patients with ATM.&#xD;
&#xD;
        3. Improve medical decision making.&#xD;
&#xD;
        4. Improve quality of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2037</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Survival to birth</measure>
    <time_frame>6 months</time_frame>
    <description>Number of fetuses diagnosed with alpha thalassemia who survive to birth, compared to number of fetuses diagnosed with alpha thalassemia who have fetal demise or are terminated in utero. This is measured in number of fetuses alive at birth divided by number of all fetuses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vineland-3 Adaptive Behavior Scale</measure>
    <time_frame>10-15 years</time_frame>
    <description>Results of neurodevelopmental testing using the Vineland Adaptive Behavior Scale version 3. The Vineland-3 scoring system is based on scores for three specific adaptive behavior domains: Communication, Daily Living Skills, and Socialization. The domain scores are expressed as standard scores with a mean of 100 and standard deviation of 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at birth</measure>
    <time_frame>6 months</time_frame>
    <description>Gestational age of the child at birth. This is measured in weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>1 year</time_frame>
    <description>Duration (if any) of requiring mechanical ventilation after birth. This is measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>6 months-1 year</time_frame>
    <description>Duration of the child's hospitalization after birth. This is measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of hydrops</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate whether receiving fetal therapy leads hydrops fetalis to resolve. This is measured by ultrasound findings.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Alpha-Thalassemia</condition>
  <condition>Alpha Thalassemia Major</condition>
  <condition>Alpha Thalassemia Minor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be either self-enrolled, or enrolled through their prenatal provider&#xD;
        (obstetrician, genetic counselor) or postnatal provider (hematologist, pediatrician).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of alpha thalassemia (prenatal or postnatal) with genotype consistent with&#xD;
             ATM or BHFS phenotype&#xD;
&#xD;
          -  referred to the University of California, San Francisco Fetal Treatment Center for&#xD;
             fetal diagnosis, management and/or evaluation for the ongoing in utero stem cell&#xD;
             transplantation clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tippi C MacKenzie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Billie Lianoglou, LCGC</last_name>
    <phone>(415) 476-2461</phone>
    <email>billie.lianoglou@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tippi C MacKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kreger EM, Singer ST, Witt RG, Sweeters N, Lianoglou B, Lal A, Mackenzie TC, Vichinsky E. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenat Diagn. 2016 Dec;36(13):1242-1249. doi: 10.1002/pd.4966. Epub 2016 Dec 7. Review.</citation>
    <PMID>27862048</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>alpha-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT04872179/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

